文献速递免疫规划

12-17岁对辉瑞-BNT162b2疫苗有临床显著反应者接种科兴-CoronaVac加强针的免疫原性与安全性

Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination.
PubMed 文献 · Vaccine · 2024-04-06

研究评估12-17岁青少年在接种辉瑞-BNT162b2 mRNA疫苗后出现中/重度反应者,序贯接种科兴-CoronaVac加强针的安全性与免疫原性。结果显示无严重不良事件;仅接种1剂辉瑞-BNT162b2后接种2剂科兴-CoronaVac者,中和抗体水平与接种2剂辉瑞-BNT162b2后接种1剂科兴-CoronaVac者相当;T细胞反应针对多种肽段,以Spike蛋白最高并持续至接种后150天。

要点

  • 对辉瑞-BNT162b2有中/重度反应的12-17岁青少年,异源接种科兴-CoronaVac加强针安全,无严重不良事件报告。
  • 1剂辉瑞-BNT162b2后接种2剂科兴-CoronaVac者,中和抗体水平与2剂辉瑞-BNT162b2后接种1剂科兴-CoronaVac者相当。
  • T细胞反应针对膜蛋白、核蛋白1和2等多种肽段,Spike蛋白水平最高并持续至接种后150天。

核心结论

  • 12-17岁青少年对辉瑞-BNT162b2 mRNA疫苗出现中/重度反应后,异源接种科兴-CoronaVac加强针安全,无严重不良事件报告。

研究设计与样本

  • 研究对象为12-17岁青少年,对辉瑞-BNT162b2 mRNA疫苗有中/重度反应,接种科兴-CoronaVac加强针。

主要发现

  • 仅接种1剂辉瑞-BNT162b2后接种2剂科兴-CoronaVac者,中和抗体水平与接种2剂辉瑞-BNT162b2后接种1剂科兴-CoronaVac者相当。
  • 接种1剂辉瑞-BNT162b2后接种2剂科兴-CoronaVac的青少年,T细胞反应针对包括膜蛋白、核蛋白1和2在内的广谱肽段,Spike蛋白水平最高,并持续至接种后150天。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vaccines achieved neutralizing antibody levels which were comparable to those who had received 2 doses of Pfizer-BNT162b2 vaccines followed by 1 dose of Sinovac-CoronaVac vaccination. Adolescents with 1 Pfizer-BNT162b2 followed by 2 Sinovac-CoronaVac vaccines developed T-cell responses against broad peptides including membrane, nucleoprotein 1 and 2 but levels were highest for Spike protein and lasted until day 150 post-vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chong CY, Kam KQ, Zhang J, et al. Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination. Vaccine. 2024. PMID: 38584057. doi:10.1016/j.vaccine.2024.04.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。